Parallax Launches Secure Good
Health Outcomes Telehealth Application for Immediate Free
Download
Parallax Announces Patented Telehealth
Initiative to Help Healthcare Providers Better Communicate with
Their Patients and Reduce ER Admissions
NEW YORK, NY -- March 25, 2020 -- InvestorsHub NewsWire
-- Parallax Health Sciences,
Inc. (PRLX)
(''Parallax'' or the ''Company''), an outcome-driven connected
healthcare company, today announced that its Good Health
OutcomesTM Telehealth, diagnostic and Remote
Patient Monitoring Mobile App is available for immediate download
at zero cost to the patient from Apple’s App Store and Google Play
store. The application is also located at www.goodhealthoutcomes.com.
Nathaniel Bradley, Chief Technology Officer of Parallax Health
Sciences, Inc. and the architect of the Good Health
OutcomesTM platform, stated that he believes, “Our
healthcare system is being stressed to its limits, on all fronts by
the Coronavirus, (“COVID-19”) and America’s hospitals are facing
one of their greatest threats to their continued operations.” Mr.
Bradley continued, “The hospital system will reach a tipping point,
sooner rather than later, and we all must look at ways to reduce
mass admissions if we can do so. America’s hospital system cannot
take the projected onslaught of people all coming into the ER in a
compressed time period, without some way to prioritize admission.
The patented Good Health OutcomesTM platform can
allow secure HIPAA compliant communications with any healthcare
provider, and deliver information on symptoms and biometric data,
such as temperature, so that doctors may begin to prioritize
admissions, and in some cases send nurses and clinicians to homes
to provide COVID-19 testing.”
Paul Arena, Chief Executive Officer of Parallax Health Sciences,
Inc., commented, “Being based here in New York City and seeing
firsthand how this virus and its impact are affecting lives, I
cannot stress enough the urgency of a great Telehealth solution
such as the Good Health OutcomesTM platform." Mr.
Arena continued, “We hope people take advantage of this at a time
where we all need to just stay put in our homes if we can do so.
People can go and download for free and then go to the Good Health
OutcomesTM site to sign in and follow
directions.”
About Parallax Diagnostics
Parallax Diagnostics is a bio-medical company and wholly owned
subsidiary of Parallax Health Sciences, Inc. Parallax Diagnostics
owns a line of 26 FDA approved, Point of Care diagnostic tests on a
single platform in the area of infectious disease, cardiac, medical
conditions, drugs of abuse, and pregnancy. Parallax Diagnostics is
developing a novel, handheld diagnostic testing system that is
simple, rapid and elegant, offering the potential to transform the
diagnostic landscape by transitioning critical tests from the
centralized lab directly to the hands of the physician or
clinicians. Our focus is on tests that detect and/or monitor
infectious diseases.
About Parallax Health Sciences
Parallax Health Sciences is a leading-edge technology,
outcome-driven telehealth company that allows for cost-effective
remote diagnosis, treatment, and monitoring of patients through
proprietary platforms of integrated products and services. The
Company's interoperable novel applications provide patients
point-of-care testing and monitoring with information communicated
via internet-based mobile phone applications that are agnostic as
to operating system and are built on highly sophisticated data
analytics. Information is retrieved in real-time by physicians who
are monitoring patients with chronic diseases or through biometric
feedback for health-related behavior modification, and is automated
for integration into electronic health records. The Company's
products and offerings capitalize on the digital transformation in
healthcare for improved patient compliance, diagnosis and
treatment, and support healthcare system cost savings and
efficiencies. For more information, please
visit www.parallaxhealthsciences.com or www.parallaxcare.com.
Forward-Looking Statements
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements regarding our expected future financial position,
results of operations, cash flows, financing plans, business
strategy, products and services, competitive positions, growth
opportunities, plans and objectives of management for future
operations, as well as statements that include words such as
"anticipate," "if," "believe," "plan," "estimate," "expect,"
"intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. All forward-looking
statements involve risks, uncertainties and contingencies, many of
which are beyond our control, which may cause actual results,
performance, or achievements to differ materially from anticipated
results, performance, or achievements. Factors that may cause
actual results to differ materially from those in the
forward-looking statements include those set forth in our Form 10-K
and other reports filed with the SEC. We are under no obligation to
(and expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
Investor Contact:
Paul Arena,
CEO
paul@parallaxcare.com
cell
404-915-8449
Parallax Health Sciences (CE) (USOTC:PRLX)
Historical Stock Chart
From May 2024 to Jun 2024
Parallax Health Sciences (CE) (USOTC:PRLX)
Historical Stock Chart
From Jun 2023 to Jun 2024